CoChat

Twenty Years of Ferroportin Disease: A Review or An Update of Published Clinical, Biochemical, Molecular, and Functional Features

Open access
Vlasveld, L. Tom, Janssen, Roel, Bardou-Jacquet, Edouard, Venselaar, Hanka, Hamdi-Roze, Houda, Drakesmith, Hal, Swinkels, Dorine W. · 2019 · Pharmaceuticals

The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.

Abstract

Iron overloading disorders linked to mutations in ferroportin have diverse phenotypes in vivo, and the effects of mutations on ferroportin in vitro range from loss of function (LOF) to gain of function (GOF) with hepcidin resistance. We reviewed 359 patients with 60 ferroportin variants. Overall, macrophage iron overload and low/normal transferrin saturation (TSAT) segregated with mutations that caused LOF, while GOF mutations were linked to high TSAT and parenchymal iron accumulation. However, the pathogenicity of individual variants is difficult to establish due to the lack of sufficiently reported data, large inter-assay variability of functional studies, and the uncertainty associated with the performance of available in silico prediction models. Since the phenotypes of hepcidin-resistant GOF variants are indistinguishable from the other types of hereditary hemochromatosis (HH), these variants may be categorized as ferroportin-associated HH, while the entity ferroportin disease may be confined to patients with LOF variants. To further improve the management of ferroportin disease, we advocate for a global registry, with standardized clinical analysis and validation of the functional tests preferably performed in human-derived enterocytic and macrophagic cell lines. Moreover, studies are warranted to unravel the definite structure of ferroportin and the indispensable residues that are essential for functionality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph12030132

Cites

151 of 151 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Box plots (Whiskers: min to max) of transferrin saturation (TSAT) in individuals with ferroportin variants. Only the variants with at least five reported TSAT levels in patients are included. Red: GOF without or conflicting data about hepcidin sensitivity; Pink: GOF hepcidin-resistant variants; Green: LOF without or conflicting data about hepcidin sensitivity; Light blue: LOF hepcidin-resistant variants; Blue: LOF hepcidin-sensitive variants; Gray: No data available.
Figure 1 Box plots (Whiskers: min to max) of transferrin saturation (TSAT) in individuals with ferroportin variants. Only the variants with at least five reported TSAT levels in patients are included. Red: GOF without or conflicting data about hepcidin sensitivity; Pink: GOF hepcidin-resistant variants; Green: LOF without or conflicting data about hepcidin sensitivity; Light blue: LOF hepcidin-resistant variants; Blue: LOF hepcidin-sensitive variants; Gray: No data available.CC BY · PubMed Central
Figure 2 Iron parameters for the different ferroportin variants. Mean (+ SD) of (A) serum iron, (B) transferrin saturation, and (C) ferritin as measured in patient samples for the function of variant (LOF = loss-of-function, GOF = gain-of-function) and the effect of hepcidin (hep resistant = hepcidin-resistant, hep sensitive = hepcidin-sensitive) on the iron transport capacity, as assessed by in vitro functional tests. TSAT = transferrin saturation. The Student’s t-test was applied to determine the difference between serum iron and TSAT, while the Mann–Whitney U-test test was applied for ferritin. Displayed p values, serum iron, and TSAT are according to the Student’s t-test. Displayed p values ferritin according to the Mann–Whitney U-test.
Figure 2 Iron parameters for the different ferroportin variants. Mean (+ SD) of (A) serum iron, (B) transferrin saturation, and (C) ferritin as measured in patient samples for the function of variant (LOF = loss-of-function, GOF = gain-of-function) and the effect of hepcidin (hep resistant = hepcidin-resistant, hep sensitive = hepcidin-sensitive) on the iron transport capacity, as assessed by in vitro functional tests. TSAT = transferrin saturation. The Student’s t-test was applied to determine the difference between serum iron and TSAT, while the Mann–Whitney U-test test was applied for ferritin. Displayed p values, serum iron, and TSAT are according to the Student’s t-test. Displayed p values ferritin according to the Mann–Whitney U-test.CC BY · PubMed Central
Figure 3 The two-dimensional (2D) structure of ferroportin protein adapted from Liu and Wallace [6,56], revealing 12 transmembrane helices and six extracellular and five intracellular segments. All the variants described in this review are shown as hepcidin-resistant (pink), hepcidin-sensitive or neutral (purple) and hepcidin conflicting/uncertain/unknown (red) GOF variants (squares). and hepcidin resistant (light blue), hepcidin sensitive (dark blue), and hepcidin conflicting-uncertain-unknown (green) LOF variants (dots), or non-classified variants (grey asterix).
Figure 3 The two-dimensional (2D) structure of ferroportin protein adapted from Liu and Wallace [6,56], revealing 12 transmembrane helices and six extracellular and five intracellular segments. All the variants described in this review are shown as hepcidin-resistant (pink), hepcidin-sensitive or neutral (purple) and hepcidin conflicting/uncertain/unknown (red) GOF variants (squares). and hepcidin resistant (light blue), hepcidin sensitive (dark blue), and hepcidin conflicting-uncertain-unknown (green) LOF variants (dots), or non-classified variants (grey asterix).CC BY · PubMed Central
Figure 4 3D model of ferroportin. (A). Overview. Ferroportin facing outward position. Top: extracellular; Bottom: intracellular. (B). Localization of hepcidin-resistant GOF variants. View inside the “channel” from extracellular to intracellular. Six (Cys326Tyr, Cys326Ser, Tyr333His, Tyr501Cys, Asp504Asn, and His507Arg) of the seven residues of GOF hepcidin-resistant variants are located inside the channel. The Ala69, Val72, Asn144, Gln182, and Ser338 residues are also located inside the channel. However, these variants have conflicting or no data on hepcidin sensitivity. (C). Clustering of LOF variants at the intracellular side of ferroportin. View inside the channel from extracellular to intracellular. Red: GOF without or conflicting data about hepcidin sensitivity; Pink: GOF hepcidin-resistant variants; Purple: GOF hepcidin-sensitive or neutral variants; Green: LOF without or conflicting data about hepcidin sensitivity; Light blue: LOF hepcidin-resistant variants; Blue: LOF hepcidin-sensitive variants. We used bacterial ferroportin for the 3D model (PDB file 5AYN).
Figure 4 3D model of ferroportin. (A). Overview. Ferroportin facing outward position. Top: extracellular; Bottom: intracellular. (B). Localization of hepcidin-resistant GOF variants. View inside the “channel” from extracellular to intracellular. Six (Cys326Tyr, Cys326Ser, Tyr333His, Tyr501Cys, Asp504Asn, and His507Arg) of the seven residues of GOF hepcidin-resistant variants are located inside the channel. The Ala69, Val72, Asn144, Gln182, and Ser338 residues are also located inside the channel. However, these variants have conflicting or no data on hepcidin sensitivity. (C). Clustering of LOF variants at the intracellular side of ferroportin. View inside the channel from extracellular to intracellular. Red: GOF without or conflicting data about hepcidin sensitivity; Pink: GOF hepcidin-resistant variants; Purple: GOF hepcidin-sensitive or neutral variants; Green: LOF without or conflicting data about hepcidin sensitivity; Light blue: LOF hepcidin-resistant variants; Blue: LOF hepcidin-sensitive variants. We used bacterial ferroportin for the 3D model (PDB file 5AYN).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 151 references

Research works printed but not linked: 4

  1. 2015, A Pediatric Case Report of Ferroportin Disease, J. Pediatr. Gastroenterol. Nutr., 63, e205
  2. Relvas, 2009, Novel human pathological mutation: Gene Symbol: SLC40A1; Disease: Haemochromatosis, type IV, Hum. Genet., 125, 338
  3. Muehlenberg, 2014, [Family with marked hyperferritinemia as a result of hemochromatosis type 4 (ferroportin disease)], Z. Gastroenterol., 52, 1075
  4. Caetano, G., Relvas, L., Bento, C., Silveira, M.P., and Ribeiro, L. (2009, January 7–11). Atypical iron deficiency anemia—Association of two new mutations in ferroportin and TMPRSS6 genes. Proceedings of the International BioIron Society Annual Meeting, Porto, Portugal.

Cited by

Metadata

Authors
Vlasveld, L. T., Janssen, R., Bardou-Jacquet, E., Venselaar, H., Hamdi-Roze, H., Drakesmith, H., & Swinkels, D. W.
Affiliations
  • Bronovo Hospital (NL)
  • Radboud University Medical Center (NL)
  • Liver Diseases Department, French Reference Centre for Rare Iron Overload Diseases of Genetic Origin, University Hospital Pontchaillou, 35033 Rennes, France
  • Molecular Genetics Department, French Reference Centre for Rare Iron Overload Diseases of Genetic Origin, University Hospital Pontchaillou, 35033 Rennes, France
  • University of Oxford (GB)
Corresponding author
Swinkels, Dorine W.
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2019-09-09
Volume
12
Issue
3
Pages
132
ISSN
1424-8247 (ISSN-L)
OpenAlex
W2972637634
Cited by
57
References
150
Citations by year
2026: 4 · 2025: 9 · 2024: 9 · 2023: 9 · 2022: 1 · 2021: 14 · 2020: 9 · 2019: 2
FWCI
1.04
Type
journal article
Language
en
Open access
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Radboud Repository (Radboud University) (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
Funders
Medical Research Council (MC_UU_00008/10)
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords
ferroportin disease, iron overload, hereditary hemochromatosis, loss-of-function mutations, gain-of-function mutations, transferrin saturation, variant pathogenicity, functional assays, in silico prediction models, patient registry

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.